BACKGROUND: Involuntary movements, or dyskinesia, represent a debilitating complication of dopamine replacement therapy for Parkinson disease (PD). The transcription factor DeltaFosB accumulates in the denervated striatum and dimerizes primarily with JunD upon repeated L-3,4-dihydroxyphenylalanine (L-DOPA) administration. Previous studies in rodents have shown that striatal DeltaFosB levels accurately predict dyskinesia severity and indicate that this transcription factor may play a causal role in the dyskinesia sensitization process. METHODS: We asked whether the correlation previously established in rodents extends to the best nonhuman primate model of PD, the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-lesioned macaque. We used western blotting and quantitative polymerase chain reaction (PCR) to compare DeltaFosB protein and messenger RNA (mRNA) levels across two subpopulations of macaques with differential dyskinesia severity. Second, we tested the causal implication of DeltaFosB in this primate model. Serotype 2 adeno-associated virus (AAV2) vectors were used to overexpress, within the motor striatum, either DeltaFosB or DeltaJunD, a truncated variant of JunD lacking a transactivation domain and therefore acting as a dominant negative inhibitor of DeltaFosB. RESULTS: A linear relationship was observed between endogenous striatal levels of DeltaFosB and the severity of dyskinesia in Parkinsonian macaques treated with L-DOPA. Viral overexpression of DeltaFosB did not alter dyskinesia severity in animals previously rendered dyskinetic, whereas the overexpression of DeltaJunD dramatically dropped the severity of this side effect of L-DOPA without altering the antiparkinsonian activity of the treatment. CONCLUSIONS: These results establish a mechanism of dyskinesia induction and maintenance by L-DOPA and validate a strategy, with strong translational potential, to deprime the L-DOPA-treated brain.
BACKGROUND:Involuntary movements, or dyskinesia, represent a debilitating complication of dopamine replacement therapy for Parkinson disease (PD). The transcription factor DeltaFosB accumulates in the denervated striatum and dimerizes primarily with JunD upon repeated L-3,4-dihydroxyphenylalanine (L-DOPA) administration. Previous studies in rodents have shown that striatal DeltaFosB levels accurately predict dyskinesia severity and indicate that this transcription factor may play a causal role in the dyskinesia sensitization process. METHODS: We asked whether the correlation previously established in rodents extends to the best nonhuman primate model of PD, the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-lesioned macaque. We used western blotting and quantitative polymerase chain reaction (PCR) to compare DeltaFosB protein and messenger RNA (mRNA) levels across two subpopulations of macaques with differential dyskinesia severity. Second, we tested the causal implication of DeltaFosB in this primate model. Serotype 2 adeno-associated virus (AAV2) vectors were used to overexpress, within the motor striatum, either DeltaFosB or DeltaJunD, a truncated variant of JunD lacking a transactivation domain and therefore acting as a dominant negative inhibitor of DeltaFosB. RESULTS: A linear relationship was observed between endogenous striatal levels of DeltaFosB and the severity of dyskinesia in Parkinsonian macaques treated with L-DOPA. Viral overexpression of DeltaFosB did not alter dyskinesia severity in animals previously rendered dyskinetic, whereas the overexpression of DeltaJunD dramatically dropped the severity of this side effect of L-DOPA without altering the antiparkinsonian activity of the treatment. CONCLUSIONS: These results establish a mechanism of dyskinesia induction and maintenance by L-DOPA and validate a strategy, with strong translational potential, to deprime the L-DOPA-treated brain.
Authors: Venetia Zachariou; Carlos A Bolanos; Dana E Selley; David Theobald; Michael P Cassidy; Max B Kelz; Tamara Shaw-Lutchman; Olivier Berton; Laura J Sim-Selley; Ralph J Dileone; Arvind Kumar; Eric J Nestler Journal: Nat Neurosci Date: 2006-01-15 Impact factor: 24.884
Authors: P K Tekumalla; F Calon; Z Rahman; S Birdi; A H Rajput; O Hornykiewicz; T Di Paolo; P J Bédard; E J Nestler Journal: Biol Psychiatry Date: 2001-11-15 Impact factor: 13.382
Authors: E Bezard; S Dovero; C Prunier; P Ravenscroft; S Chalon; D Guilloteau; A R Crossman; B Bioulac; J M Brotchie; C E Gross Journal: J Neurosci Date: 2001-09-01 Impact factor: 6.167
Authors: Jennifer Kaufling; Elisabeth Waltisperger; Romain Bourdy; Antoine Valera; Pierre Veinante; Marie-José Freund-Mercier; Michel Barrot Journal: Br J Pharmacol Date: 2010-12 Impact factor: 8.739
Authors: Allison E Girasole; Matthew Y Lum; Diane Nathaniel; Chloe J Bair-Marshall; Casey J Guenthner; Liqun Luo; Anatol C Kreitzer; Alexandra B Nelson Journal: Neuron Date: 2018-02-01 Impact factor: 17.173
Authors: Haili Zhang; Ming Zheng; Manhong Wu; Dan Xu; Toshihiko Nishimura; Yuki Nishimura; Rona Giffard; Xiaoxing Xiong; Li Jun Xu; J David Clark; Peyman Sahbaie; David L Dill; Gary Peltz Journal: Genetics Date: 2016-03-18 Impact factor: 4.562